Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vicki Thallas-Bonke

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
Current Opinion in Nephrology and Hypertension|November 18, 2014
Nox-4 and progressive kidney diseaseVicki Thallas-Bonke, Karin A M Jandeleit-Dahm, Mark E Cooper
Current Pharmaceutical Design|November 17, 2004
Advanced glycation: how are we progressing to combat this web of sugar anomalies in diabetic nephropathyJosephine M Forbes, Vicki Thallas-Bonke, Mark E Cooper, et al.
American Journal of Nephrology|June 17, 2010
Preservation of kidney function with combined inhibition of NADPH oxidase and angiotensin-converting enzyme in diabetic nephropathyVicki Thallas-Bonke, Melinda T Coughlan, Leon A Bach, et al.
Diabetes|April 28, 2011
Dedifferentiation of immortalized human podocytes in response to transforming growth factor-β: a model for diabetic podocytopathyMichal Herman-Edelstein, Merlin C Thomas, Vicki Thallas-Bonke, et al.
Diabetes|October 27, 2004
Attenuation of extracellular matrix accumulation in diabetic nephropathy by the advanced glycation end product cross-link breaker ALT-711 via a protein kinase C-alpha-dependent pathwayVicki Thallas-Bonke, Carsten Lindschau, Bishoy Rizkalla, et al.
Diabetology & Metabolic Syndrome|August 22, 2014
Ramipril inhibits AGE-RAGE-induced matrix metalloproteinase-2 activation in experimental diabetic nephropathyKei Fukami, Sho-Ichi Yamagishi, Melinda T Coughlan, et al.
Journal of the American Society of Nephrology : JASN|August 18, 2006
Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: implications for diabetic renal diseaseWendy C Burns, Stephen M Twigg, Josephine M Forbes, et al.
Nephrology (Carlton, Vic.)|October 11, 2012
Targeting the AGE-RAGE axis improves renal function in the context of a healthy diet low in advanced glycation end-product contentVicki Thallas-Bonke, Melinda T Coughlan, Adeline Ly Tan, et al.
Scientific Reports|September 22, 2019
Globally elevating the AGE clearance receptor, OST48, does not protect against the development of diabetic kidney disease, despite improving insulin secretionAowen Zhuang, Felicia Y T Yap, Domenica McCarthy, et al.
Endocrinology|November 18, 2006
Combination therapy with the advanced glycation end product cross-link breaker, alagebrium, and angiotensin converting enzyme inhibitors in diabetes: synergy or redundancy?Melinda T Coughlan, Vicki Thallas-Bonke, Josefa Pete, et al.
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
Current Opinion in Nephrology and Hypertension|November 18, 2014
Nox-4 and progressive kidney diseaseVicki Thallas-Bonke, Karin A M Jandeleit-Dahm, Mark E Cooper
Current Pharmaceutical Design|November 17, 2004
Advanced glycation: how are we progressing to combat this web of sugar anomalies in diabetic nephropathyJosephine M Forbes, Vicki Thallas-Bonke, Mark E Cooper, et al.
American Journal of Nephrology|June 17, 2010
Preservation of kidney function with combined inhibition of NADPH oxidase and angiotensin-converting enzyme in diabetic nephropathyVicki Thallas-Bonke, Melinda T Coughlan, Leon A Bach, et al.
Diabetes|April 28, 2011
Dedifferentiation of immortalized human podocytes in response to transforming growth factor-β: a model for diabetic podocytopathyMichal Herman-Edelstein, Merlin C Thomas, Vicki Thallas-Bonke, et al.
Diabetes|October 27, 2004
Attenuation of extracellular matrix accumulation in diabetic nephropathy by the advanced glycation end product cross-link breaker ALT-711 via a protein kinase C-alpha-dependent pathwayVicki Thallas-Bonke, Carsten Lindschau, Bishoy Rizkalla, et al.
Diabetology & Metabolic Syndrome|August 22, 2014
Ramipril inhibits AGE-RAGE-induced matrix metalloproteinase-2 activation in experimental diabetic nephropathyKei Fukami, Sho-Ichi Yamagishi, Melinda T Coughlan, et al.
Journal of the American Society of Nephrology : JASN|August 18, 2006
Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: implications for diabetic renal diseaseWendy C Burns, Stephen M Twigg, Josephine M Forbes, et al.
Nephrology (Carlton, Vic.)|October 11, 2012
Targeting the AGE-RAGE axis improves renal function in the context of a healthy diet low in advanced glycation end-product contentVicki Thallas-Bonke, Melinda T Coughlan, Adeline Ly Tan, et al.
Scientific Reports|September 22, 2019
Globally elevating the AGE clearance receptor, OST48, does not protect against the development of diabetic kidney disease, despite improving insulin secretionAowen Zhuang, Felicia Y T Yap, Domenica McCarthy, et al.
Endocrinology|November 18, 2006
Combination therapy with the advanced glycation end product cross-link breaker, alagebrium, and angiotensin converting enzyme inhibitors in diabetes: synergy or redundancy?Melinda T Coughlan, Vicki Thallas-Bonke, Josefa Pete, et al.
Pageof 3